Journal of Clinical Oncology, Vol 7, 415-424, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy

WS Dalton, TM Grogan, PS Meltzer, RJ Scheper, BG Durie, CW Taylor, TP Miller and SE Salmon
Department of Medicine, University of Arizona, College of Medicine, Tucson.

The B-cell neoplasms, multiple myeloma and non-Hodgkin's lymphoma, frequently become drug resistant, despite initial responses to chemotherapeutic drugs. Tumor cells from eight patients with clinically drug-refractory disease were evaluated by immuno-histochemical staining for monoclonal immunoglobulin (Ig) expression, nuclear proliferation antigen, P-glycoprotein (P-gly) expression, and other cellular antigens. P-gly was detected on tumor cells from six of eight patients with drug-resistant disease. Of the six patients with P-gly-positive tumors, five patients had advanced multiple myeloma and one had a drug- refractory non-Hodgkin's lymphoma. Cellular RNA analysis confirmed the over-expression of P-gly. In an effort to overcome drug resistance, a pilot study evaluated possible verapamil enhancement of chemotherapy in these eight patients. All patients had developed progressive disease while receiving a regimen containing vincristine and doxorubicin, and seven of eight patients had previously received continuous infusion vincristine and doxorubicin plus oral dexamethasone (VAD). At the time of progressive disease, continuous infusion verapamil was added to the VAD regimen. Three of the eight patients who were refractory to vincristine and doxorubicin alone responded when verapamil was added to VAD. The three patients who responded had P-gly-positive tumors. Verapamil increased the intracellular accumulation of doxorubicin and vincristine in vitro for both a P-gly-positive myeloma cell line and tumor cells from two patients with end-stage myeloma which over- expressed P-gly. The dose-limiting side effect associated with the addition of verapamil to chemotherapy was temporary impairment of cardiac function, manifest as hypotension and cardiac arrhythmia. We conclude that P-gly expression occurs in drug-refractory B-cell neoplasms and may contribute to the development of clinical drug resistance. However, other factors, such as the proliferative activity of the tumor, may also play a role in determining response to chemotherapy. The administration of verapamil along with VAD chemotherapy may partially circumvent drug resistance in patients whose tumors over-express P-gly.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. M. Evens, P. Lecane, D. Magda, S. Prachand, S. Singhal, J. Nelson, R. A. Miller, R. B. Gartenhaus, and L. I. Gordon Motexafin gadolinium generates reactive oxygen species and induces apoptosis in sensitive and highly resistant multiple myeloma cells Blood, February 1, 2005; 105(3): 1265 - 1273. [Abstract] [Full Text] [PDF]

				D. Trompier, X.-B. Chang, R. Barattin, A. d. M. d'Hardemare, A. Di Pietro, and H. Baubichon-Cortay Verapamil and Its Derivative Trigger Apoptosis through Glutathione Extrusion by Multidrug Resistance Protein MRP1 Cancer Res., July 15, 2004; 64(14): 4950 - 4956. [Abstract] [Full Text] [PDF]

				S. Cisternino, C. Mercier, F. Bourasset, F. Roux, and J.-M. Scherrmann Expression, Up-Regulation, and Transport Activity of the Multidrug-Resistance Protein Abcg2 at the Mouse Blood-Brain Barrier Cancer Res., May 1, 2004; 64(9): 3296 - 3301. [Abstract] [Full Text] [PDF]

				J. McCafferty-Grad, N. J. Bahlis, N. Krett, T. M. Aguilar, I. Reis, K. P. Lee, and L. H. Boise Arsenic trioxide uses caspase-dependent and caspase-independent death pathways in myeloma cells Mol. Cancer Ther., November 1, 2003; 2(11): 1155 - 1164. [Abstract] [Full Text] [PDF]

				H. Wu, W. N. Hait, and J.-M. Yang Small Interfering RNA-induced Suppression of MDR1 (P-Glycoprotein) Restores Sensitivity to Multidrug-resistant Cancer Cells Cancer Res., April 1, 2003; 63(7): 1515 - 1519. [Abstract] [Full Text] [PDF]

				W. S. Dalton Targeting the Mitochondria: An Exciting New Approach to Myeloma Therapy: Commentary re: N. J. Bahlis et al., Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic Acid-mediated Depletion of Intracellular Glutathione for the Treatment of Relapsed/Refractory Multiple Myeloma. Clin. Cancer Res., 8: 3658-3668, 2002. Clin. Cancer Res., December 1, 2002; 8(12): 3643 - 3645. [Full Text] [PDF]

				N. J. Bahlis, J. McCafferty-Grad, I. Jordan-McMurry, J. Neil, I. Reis, M. Kharfan-Dabaja, J. Eckman, M. Goodman, H. F. Fernandez, L. H. Boise, et al. Feasibility and Correlates of Arsenic Trioxide Combined with Ascorbic Acid-mediated Depletion of Intracellular Glutathione for the Treatment of Relapsed/Refractory Multiple Myeloma Clin. Cancer Res., December 1, 2002; 8(12): 3658 - 3668. [Abstract] [Full Text] [PDF]

				V. J. Spanswick, C. Craddock, M. Sekhar, P. Mahendra, P. Shankaranarayana, R. G. Hughes, D. Hochhauser, and J. A. Hartley Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma Blood, June 17, 2002; 100(1): 224 - 229. [Abstract] [Full Text] [PDF]

				J.-A. Liang, Y.-C. Shiau, S.-N. Yang, F.-J. Lin, A. Kao, and C.-C. Lee Prediction of Chemotherapy Response in Untreated Malignant Lymphomas Using Technetium-99m Methoxyisobutylisonitrile Scan: Comparison with P-glycoprotein Expression and Other Prognostic Factors. A Preliminary Report Jpn. J. Clin. Oncol., April 1, 2002; 32(4): 140 - 145. [Abstract] [Full Text] [PDF]

				J. M. Grad, N. J. Bahlis, I. Reis, M. M. Oshiro, W. S. Dalton, and L. H. Boise Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells Blood, August 1, 2001; 98(3): 805 - 813. [Abstract] [Full Text] [PDF]

				E. R. Gaynor, J. M. Unger, T. P. Miller, T. M. Grogan, L. A. White Jr, G. M. Mills, S. P. Balcerzak, M. Varterasian, M. LeBlanc, and R. I. Fisher Infusional CHOP Chemotherapy (CVAD) With or Without Chemosensitizers Offers No Advantage Over Standard CHOP Therapy in the Treatment of Lymphoma: A Southwest Oncology Group Study J. Clin. Oncol., February 1, 2001; 19(3): 750 - 755. [Abstract] [Full Text] [PDF]

				A. Patnaik, E. Warner, M. Michael, M. J. Egorin, M. J. Moore, L. L. Siu, P. M. Fracasso, S. Rivkin, I. Kerr, M. Litchman, et al. Phase I Dose-Finding and Pharmacokinetic Study of Paclitaxel and Carboplatin With Oral Valspodar in Patients With Advanced Solid Tumors J. Clin. Oncol., November 1, 2000; 18(21): 3677 - 3689. [Abstract] [Full Text] [PDF]

				D. W. Loe, R. G. Deeley, and S. P. C. Cole Verapamil Stimulates Glutathione Transport by the 190-kDa Multidrug Resistance Protein 1 (MRP1) J. Pharmacol. Exp. Ther., May 1, 2000; 293(2): 530 - 538. [Abstract] [Full Text]

				W. S. Dalton and R. J. Scheper Lung Resistance-Related Protein: Determining Its Role in Multidrug Resistance J Natl Cancer Inst, October 6, 1999; 91(19): 1604 - 1605. [Full Text] [PDF]

				M. E.P. Smeets, R. A.P. Raymakers, G. Vierwinden, A. H.M. Pennings, H. Wessels, and T. de Witte Triggering Noncycling Hematopoietic Progenitors and Leukemic Blasts to Proliferate Increases Anthracycline Retention and Toxicity by Downregulating Multidrug Resistance Blood, October 1, 1999; 94(7): 2414 - 2423. [Abstract] [Full Text] [PDF]

				T. Shoshani, S. Zhang, S. Dey, I. Pastan, and M. M. Gottesman Analysis of Random Recombination between Human MDR1 and Mouse Mdr1a cDNA in a pHaMDR-Dihydrofolate Reductase Bicistronic Expression System Mol. Pharmacol., October 1, 1998; 54(4): 623 - 630. [Abstract] [Full Text]

				A. Demmer, H. Thole, P. Kubesch, T. Brandt, M. Raida, R. Fislage, and B. Tummler Localization of the Iodomycin Binding Site in Hamster P-glycoprotein J. Biol. Chem., August 15, 1997; 272(33): 20913 - 20919. [Abstract] [Full Text] [PDF]

				A. H. Schinkel, U. Mayer, E. Wagenaar, C. A. A. M. Mol, L. van Deemter, J. J. M. Smit, M. A. van der Valk, A. C. Voordouw, H. Spits, O. van Tellingen, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins PNAS, April 15, 1997; 94(8): 4028 - 4033. [Abstract] [Full Text] [PDF]

				T. H. Landowski, M. C. Gleason-Guzman, and W. S. Dalton Selection for Drug Resistance Results in Resistance to Fas-Mediated Apoptosis Blood, March 15, 1997; 89(6): 1854 - 1861. [Abstract] [Full Text] [PDF]

				A. J. Szczepek, P.L. Bergsagel, L. Axelsson, C. B. Brown, A. R. Belch, and L. M. Pilarski CD34+ Cells in the Blood of Patients With Multiple Myeloma Express CD19 and IgH mRNA and Have Patient-Specific IgH VDJ Gene Rearrangements Blood, March 1, 1997; 89(5): 1824 - 1833. [Abstract] [Full Text] [PDF]

				G. Chen, G. E. Duran, K. A. Steger, N. J. Lacayo, J.-P. Jaffrezou, C. Dumontet, and B. I. Sikic Multidrug-resistant Human Sarcoma Cells with a Mutant P-Glycoprotein, Altered Phenotype, and Resistance to Cyclosporins J. Biol. Chem., February 28, 1997; 272(9): 5974 - 5982. [Abstract] [Full Text] [PDF]

				H. TAKESHITA, M. C. GEBHARDT, D. S. SPRINGFIELD, K. KUSUZAKI, and H. J. MANKIN Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines J. Bone Joint Surg. Am., March 1, 1996; 78(3): 366 - 75. [Abstract] [Full Text]

				N. Baldini, K. Scotlandi, G. Barbanti-Brodano, M. C. Manara, D. Maurici, G. Bacci, F. Bertoni, P. Picci, S. Sottili, M. Campanacci, et al. Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome N. Engl. J. Med., November 23, 1995; 333(21): 1380 - 1385. [Abstract] [Full Text] [PDF]

				C.H. Lee, G. Bradley, and V. Ling Expression of P-Glycoprotein in Normal and Malignant Rat Liver Cells Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 607 - 615. [Abstract] [PDF]

				M. A. Dimopoulos, B. Barlogie, T. L. Smith, and R. Alexanian High Serum Lactate Dehydrogenase Level as a Marker for Drug Resistance and Short Survival in Multiple Myeloma Ann Intern Med, December 15, 1991; 115(12): 931 - 935. [Abstract] [PDF]

				M. Rothenberg and B. A. Chabner Oncology JAMA, May 16, 1990; 263(19): 2667 - 2668. [Abstract] [PDF]